Register for email alerts and news feeds:
This journal | BMJ Group
rss
Thorax 2008;63:847-849; doi:10.1136/thx.2007.093971
Copyright © 2008 BMJ Publishing Group Ltd & British Thoracic Society.

EDITORIALS

Leukotriene receptor antagonist therapy and Churg–Strauss syndrome: culprit or innocent bystander?

Richard Beasley1, Susan Bibby1, Mark Weatherall2

1 Medical Research Institute of New Zealand, Wellington, New Zealand
2 University of Otago Wellington, Wellington, New Zealand

Correspondence to:
Professor Richard Beasley, Medical Research Institute of New Zealand, PO Box 10055, Wellington 6143, New Zealand; Richard.Beasley@mrinz.ac.nz

The first 150 words of the full text of this article appear below.

Randomised controlled trials can provide strong evidence of the efficacy (or lack) of new drug treatments as well as the occurrence of common side effects.1 However, clinical safety issues can arise after new medications receive regulatory approval, particularly in relation to rare serious adverse events.2 Investigation of rare adverse events is often fraught with difficulty, leading to uncertainty, particularly when there is conflicting evidence from research utilising different methodologies. One recent example is the observed association between leukotriene receptor antagonist (LTRA) therapy, used in the treatment of asthma, and Churg–Strauss syndrome (CSS), a vasculitis of uncertain aetiology (also known as allergic granulomatous angiitis). CSS is certainly both rare and serious, with a background incidence of 3 per million per year in the general population, and a 1 year mortality rate of 7%.35

Soon after the introduction of LTRAs (zafirlukast, pranlukast and montelukast), numerous case reports and case series were published . . . [Full text of this article]


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

Relevant Articles

Airwaves
Wisia Wedzicha
Thorax 2008 63: i. [Extract] [Full Text] [PDF]

Churg–Strauss syndrome and leukotriene antagonist use: a respiratory perspective
N Nathani, M A Little, H Kunst, D Wilson, and D R Thickett
Thorax 2008 63: 883-888. [Abstract] [Full Text] [PDF]

This article has been cited by other articles:

  • Kamp, D. W. (2009). Drug-Induced Lung Diseases. ACCP Pulmonary Med Brd Rev 25: 319-344 [Full Text]  

This Article

Services
Citing Articles
Google Scholar
PubMed
Topic Collections
Bookmark with

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

Chest Medicine Jobs

Chest Medicine Jobs